Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ariad Pharmaceuticals, Inc.    ARIA

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Ariad Pharmaceuticals, Inc. : ARIA, XOMA, PRAN and NIHD added to NASDAQ Active Stock Watch List at EPR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/31/2013 | 03:15pm CET

New York, NY - (ACCESSWIRE) - 10/31/2013 - Equity Profile Report initiates its NASDAQ Active Stock Weekly Watch List adding Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), XOMA Corporation (NASDAQ:XOMA), Prana Biotechnology Limited (NASDAQ:PRAN) and NII Holdings Inc. (NASDAQ:NIHD)

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients is currently down (-38.13%) on 26,575,426 shares traded after Ariad suspended sales of cancer pill Iclusig. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) is currently down (-90.81%) from its recent 52-week high, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=ARIA&SubId=AW

XOMA Corporation (NASDAQ:XOMA) a company that discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific is currently up (+4.35%) on 712,280 shares traded after XOMA Corporation announced very encouraging results from two Phase 2 clinical studies that are part of the Company's broad gevokizumab proof-of-concept program. XOMA Corporation (NASDAQ:XOMA) is currently up (+95.78%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about XOMA Corporation (NASDAQ:XOMA)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=XOMA&SubId=AW

Prana Biotechnology Limited (NASDAQ:PRAN) a company that researches and develops therapeutic drugs for the treatment of neurological disorders in Australia is currently up (+1.80%) on 563,051 shares traded after Prana's PBT2 Reversed Memory Loss in Normal Aging. Prana Biotechnology Limited (NASDAQ:PRAN) is currently up (+161.31%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Prana Biotechnology Limited (NASDAQ:PRAN)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=PRAN&SubId=AW

NII Holdings Inc. (NASDAQ:NIHD) a company that through its subsidiaries, provides wireless communication services under the Nextel brand name to businesses and individuals in Mexico, Brazil, Argentina, Peru, and Chile is currently down (-19.58%) on 2,272,972 shares traded after NII Holdings, Inc. Discussed Q3 2013 Results. NII Holdings Inc. (NASDAQ:NIHD) is currently down (-61.3%) from its recent 52-week high, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about NII Holdings Inc. (NASDAQ:NIHD)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=NIHD&SubId=AW

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.equityprofilereport.com/

Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARIAD PHARMACEUTICALS, INC
01/21 The Chicago Equity Partners Llc Invests $1,336,000 in Ariad Pharmaceuticals, ..
01/20 ARIAD PHARMACEUTICALS, INC. (NASDAQ : ARIA) Under Investigation for Investors ov..
01/20 TAKEDA PHARMACEUTICAL : Commences Cash Tender Offer for All Outstanding Shares o..
01/18 ARIAD PHARMACEUTICALS : Acquisition May Not Be in the Best Interests of ARIA Sha..
01/13 ARIAD SHAREHOLDER NOTICE : Faruqi & Faruqi, LLP Announces the Investigation of A..
01/13 Brower Piven Commences An Investigation Into The Proposed Sale Of ARIAD Pharm..
01/12 ARIAD PHARMACEUTICALS : to Present at the 35th Annual J.P. Morgan Healthcare Con..
01/12 ARIAD PHARMACEUTICALS : Takeda to acquire ARIAD Pharmaceuticals
01/11 TAKEDA PHARMACEUTICAL : to buy Ariad in $4.7 billion cash deal
01/10 ARIAD PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Terminat..
More news
Sector news : Bio Therapeutic Drugs
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
01/20 Trump Era M&A Boom?
01/11 VALEANT : Forget About Acquisition. Takeda Has Bought ARIAD
01/11 BIOTECH FORUM DAILY DIGEST : Keytruda Continues To Power Merck; Revisiting Invit..
01/10 Google Is Watching You
01/10 Takeda to acquire ARIAD Pharmaceuticals (ARIA) - M&A Call Slides
Advertisement
Financials ($)
Sales 2016 196 M
EBIT 2016 -111 M
Net income 2016 -7,07 M
Debt 2016 157 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 24,3x
EV / Sales 2017 19,4x
Capitalization 4 612 M
More Financials
Chart ARIAD PHARMACEUTICALS, INC
Duration : Period :
Ariad Pharmaceuticals, Inc Technical Analysis Chart | ARIA | US04033A1007 | 4-Traders
Full-screen chart
Technical analysis trends ARIAD PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Average target price 20,6 $
Spread / Average Target -13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Paris Panayiotopoulos President, Chief Executive Officer & Director
Alexander John Denner Chairman
Manmeet Singh Soni Chief Financial Officer, Treasurer & Executive VP
Timothy P. Clackson Chief Scientific Officer
Nicholas Ventresca Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ARIAD PHARMACEUTICALS,..90.92%4 612
AMGEN, INC.5.79%115 062
GILEAD SCIENCES, INC.-0.84%93 553
CELGENE CORPORATION-2.67%87 334
REGENERON PHARMACEUTIC..-1.23%38 239
ACTELION LTD1.18%23 977
More Results